{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:21:44Z","timestamp":1792682504292,"version":"4.5.0"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82170636,82300720,92169121, 82302508"],"award-info":[{"award-number":["82170636,82300720,92169121, 82302508"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2305100"],"award-info":[{"award-number":["2022YFC2305100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2304401"],"award-info":[{"award-number":["2022YFC2304401"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-025-04788-3","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T11:49:37Z","timestamp":1764330577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mesenchymal stem cell therapy for end-stage liver disease: adversity and opportunity"],"prefix":"10.1186","volume":"16","author":[{"given":"Shiqi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-qin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"4788_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S2468-1253(16)30005-X","volume":"1","author":"S Vento","year":"2016","unstructured":"Vento S, Cainelli F, Ashimkhanova A. End-stage liver disease in Eastern Europe and Central Asia: action is needed. Lancet Gastroenterol Hepatol. 2016;1:8\u20139.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4788_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"SK Asrani","year":"2019","unstructured":"Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70:151\u201371.","journal-title":"J Hepatol"},{"key":"4788_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","volume":"5","author":"SG Sepanlou","year":"2020","unstructured":"Sepanlou SG, et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5:245\u201366.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4788_CR4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi H, et al. Global burden of liver disease: 2023 update. J Hepatol. 2023;79:516\u201337.","journal-title":"J Hepatol"},{"key":"4788_CR5","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.cgh.2023.04.005","volume":"21","author":"NA Terrault","year":"2023","unstructured":"Terrault NA, Francoz C, Berenguer M, Charlton M, Heimbach J. Liver transplantation 2023: status report, current and future challenges. Clin Gastroenterol Hepatol. 2023;21:2150\u201366.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4788_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","volume":"44","author":"G D\u2019Amico","year":"2006","unstructured":"D\u2019Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217\u201331.","journal-title":"J Hepatol"},{"key":"4788_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1053\/jhep.2000.9124","volume":"32","author":"ND Theise","year":"2000","unstructured":"Theise ND, et al. Liver from bone marrow in humans. Hepatology. 2000;32:11\u20136.","journal-title":"Hepatology"},{"key":"4788_CR8","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/hep.20469","volume":"40","author":"K Lee","year":"2004","unstructured":"Lee K, et al. In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology. 2004;40:1275\u201384.","journal-title":"Hepatology"},{"key":"4788_CR9","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S1499-3872(12)60193-3","volume":"11","author":"X-B Wu","year":"2012","unstructured":"Wu X-B, Tao R. Hepatocyte differentiation of mesenchymal stem cells. Hepatobiliary Pancreat Dis Int. 2012;11:360\u201371.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"4788_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jhep.2013.01.018","volume":"59","author":"Z Zhang","year":"2013","unstructured":"Zhang Z, Wang F-S. Stem cell therapies for liver failure and cirrhosis. J Hepatol. 2013;59:183\u20135.","journal-title":"J Hepatol"},{"key":"4788_CR11","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1096\/fj.201600433R","volume":"30","author":"D Haldar","year":"2016","unstructured":"Haldar D, Henderson NC, Hirschfield G, Newsome P. N. Mesenchymal stromal cells and liver fibrosis: a complicated relationship. FASEB J. 2016;30:3905\u201328.","journal-title":"FASEB J"},{"key":"4788_CR12","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1053\/j.gastro.2008.03.015","volume":"134","author":"TK Kuo","year":"2008","unstructured":"Kuo TK, et al. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology. 2008;134:2111\u2013e21213.","journal-title":"Gastroenterology"},{"key":"4788_CR13","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1002\/stem.1818","volume":"32","author":"V Volarevic","year":"2014","unstructured":"Volarevic V, Nurkovic J, Arsenijevic N, Stojkovic MC, Review. Therapeutic potential of mesenchymal stem cells for the treatment of acute liver failure and cirrhosis. Stem Cells. 2014;32:2818\u201323.","journal-title":"Stem Cells"},{"key":"4788_CR14","first-page":"3052","volume":"24","author":"M Mito","year":"1992","unstructured":"Mito M, Kusano M, Kawaura Y. Hepatocyte transplantation in man. Transpl Proc. 1992;24:3052\u20133.","journal-title":"Transpl Proc"},{"key":"4788_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1053\/j.gastro.2013.11.034","volume":"146","author":"MJ Williams","year":"2014","unstructured":"Williams MJ, Clouston AD, Forbes SJ. Links between hepatic fibrosis, ductular reaction, and progenitor cell expansion. Gastroenterology. 2014;146:349\u201356.","journal-title":"Gastroenterology"},{"key":"4788_CR16","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1002\/hep.25742","volume":"56","author":"V Nobili","year":"2012","unstructured":"Nobili V, et al. Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. Hepatology. 2012;56:2142\u201353.","journal-title":"Hepatology"},{"key":"4788_CR17","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.stem.2014.04.010","volume":"14","author":"A Miyajima","year":"2014","unstructured":"Miyajima A, Tanaka M, Itoh T. Stem\/progenitor cells in liver development, homeostasis, regeneration, and reprogramming. Cell Stem Cell. 2014;14:561\u201374.","journal-title":"Cell Stem Cell"},{"key":"4788_CR18","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/ncb3203","volume":"17","author":"W-Y Lu","year":"2015","unstructured":"Lu W-Y, et al. Hepatic progenitor cells of biliary origin with liver repopulation capacity. Nat Cell Biol. 2015;17:971\u201383.","journal-title":"Nat Cell Biol"},{"key":"4788_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/hep.28326","volume":"64","author":"G Lanzoni","year":"2016","unstructured":"Lanzoni G, Cardinale V, Carpino G. The hepatic, biliary, and pancreatic network of stem\/progenitor cell niches in humans: a new reference frame for disease and regeneration. Hepatology. 2016;64:277\u201386.","journal-title":"Hepatology"},{"key":"4788_CR20","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1002\/stem.1457","volume":"31","author":"G Lanzoni","year":"2013","unstructured":"Lanzoni G, et al. Concise review: clinical programs of stem cell therapies for liver and pancreas. Stem Cells. 2013;31:2047\u201360.","journal-title":"Stem Cells"},{"key":"4788_CR21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/hepr.12772","volume":"47","author":"T Maraldi","year":"2017","unstructured":"Maraldi T, et al. Human biliary tree stem\/progenitor cells immunomodulation: role of hepatocyte growth factor. Hepatol Res. 2017;47:465\u201379.","journal-title":"Hepatol Res"},{"key":"4788_CR22","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1126\/science.282.5391.1145","volume":"282","author":"JA Thomson","year":"1998","unstructured":"Thomson JA, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282:1145\u20137.","journal-title":"Science"},{"key":"4788_CR23","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/nbt1201-1129","volume":"19","author":"S-C Zhang","year":"2001","unstructured":"Zhang S-C, Wernig M, Duncan ID, Br\u00fcstle O, Thomson JA. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol. 2001;19:1129\u201333.","journal-title":"Nat Biotechnol"},{"key":"4788_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/74447","volume":"18","author":"BE Reubinoff","year":"2000","unstructured":"Reubinoff BE, Pera MF, Fong C-Y, Trounson A, Bongso A. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol. 2000;18:399\u2013404.","journal-title":"Nat Biotechnol"},{"key":"4788_CR25","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1182\/blood-2006-08-019190","volume":"110","author":"S Levenberg","year":"2007","unstructured":"Levenberg S, Zoldan J, Basevitch Y, Langer R. Endothelial potential of human embryonic stem cells. Blood. 2007;110:806\u201314.","journal-title":"Blood"},{"key":"4788_CR26","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1053\/j.gastro.2008.10.047","volume":"136","author":"H Basma","year":"2009","unstructured":"Basma H, et al. Differentiation and transplantation of human embryonic stem Cell\u2013Derived hepatocytes. Gastroenterology. 2009;136:990\u2013e9994.","journal-title":"Gastroenterology"},{"key":"4788_CR27","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.stem.2011.05.012","volume":"8","author":"CEP Goldring","year":"2011","unstructured":"Goldring CEP, et al. Assessing the safety of stem cell therapeutics. Cell Stem Cell. 2011;8:618\u201328.","journal-title":"Cell Stem Cell"},{"key":"4788_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nbt1285","volume":"25","author":"DEC Baker","year":"2007","unstructured":"Baker DEC, et al. Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Nat Biotechnol. 2007;25:207\u201315.","journal-title":"Nat Biotechnol"},{"key":"4788_CR29","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/nbt.2051","volume":"29","author":"The International Stem Cell Initiative","year":"2011","unstructured":"The International Stem Cell Initiative. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol. 2011;29:1132\u201344.","journal-title":"Nat Biotechnol"},{"key":"4788_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/cmi.2013.60","volume":"11","author":"X Fu","year":"2014","unstructured":"Fu X. The immunogenicity of cells derived from induced pluripotent stem cells. Cell Mol Immunol. 2014;11:14\u20136.","journal-title":"Cell Mol Immunol"},{"key":"4788_CR31","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663\u201376.","journal-title":"Cell"},{"key":"4788_CR32","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861\u201372.","journal-title":"Cell"},{"key":"4788_CR33","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/nature07061","volume":"454","author":"JB Kim","year":"2008","unstructured":"Kim JB, et al. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature. 2008;454:646\u201350.","journal-title":"Nature"},{"key":"4788_CR34","doi-asserted-by":"publisher","first-page":"15720","DOI":"10.1073\/pnas.0908450106","volume":"106","author":"N Sun","year":"2009","unstructured":"Sun N, et al. Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. Proc Natl Acad Sci U S A. 2009;106:15720\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"4788_CR35","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.stem.2008.08.003","volume":"3","author":"N Maherali","year":"2008","unstructured":"Maherali N, et al. A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell. 2008;3(3):340\u20135.","journal-title":"Cell Stem Cell"},{"key":"4788_CR36","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1126\/science.1154884","volume":"321","author":"T Aoi","year":"2008","unstructured":"Aoi T, et al. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science. 2008;321:699\u2013702.","journal-title":"Science"},{"key":"4788_CR37","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nature10761","volume":"481","author":"DA Robinton","year":"2012","unstructured":"Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature. 2012;481:295\u2013305.","journal-title":"Nature"},{"key":"4788_CR38","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s13238-012-2918-4","volume":"3","author":"F Yi","year":"2012","unstructured":"Yi F, Liu G-H, Belmonte JC. I. Human induced pluripotent stem cells derived hepatocytes: rising promise for disease modeling, drug development and cell therapy. Protein Cell. 2012;3:246\u201350.","journal-title":"Protein Cell"},{"key":"4788_CR39","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/hep.23354","volume":"51","author":"K Si-Tayeb","year":"2010","unstructured":"Si-Tayeb K, et al. Highly efficient generation of human hepatocyte\u2013like cells from induced pluripotent stem cells. Hepatology. 2010;51:297\u2013305.","journal-title":"Hepatology"},{"key":"4788_CR40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cell.2009.03.034","volume":"137","author":"S Yamanaka","year":"2009","unstructured":"Yamanaka S. A fresh look at iPS cells. Cell. 2009;137:13\u20137.","journal-title":"Cell"},{"key":"4788_CR41","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nature05934","volume":"448","author":"K Okita","year":"2007","unstructured":"Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448:313\u20137.","journal-title":"Nature"},{"key":"4788_CR42","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.jhep.2019.06.030","volume":"71","author":"SJ Mun","year":"2019","unstructured":"Mun SJ, et al. Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids. J Hepatol. 2019;71:970\u201385.","journal-title":"J Hepatol"},{"key":"4788_CR43","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg0338","author":"T Tadokoro","year":"2024","unstructured":"Tadokoro T, et al. Human iPSC\u2013liver organoid transplantation reduces fibrosis through immunomodulation. Sci Transl Med. 2024. https:\/\/doi.org\/10.1126\/scitranslmed.adg0338.","journal-title":"Sci Transl Med"},{"key":"4788_CR44","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1053\/j.gastro.2020.06.010","volume":"159","author":"MNB Ramli","year":"2020","unstructured":"Ramli MNB, et al. Human pluripotent stem Cell-Derived organoids as models of liver disease. Gastroenterology. 2020;159:1471\u2013e148612.","journal-title":"Gastroenterology"},{"key":"4788_CR45","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1365-2184.1970.tb00347.x","volume":"3","author":"AJ Friedenstein","year":"1970","unstructured":"Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Prolif. 1970;3:393\u2013403.","journal-title":"Cell Prolif"},{"key":"4788_CR46","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/jor.1100090504","volume":"9","author":"AI Caplan","year":"1991","unstructured":"Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9:641\u201350.","journal-title":"J Orthop Res"},{"key":"4788_CR47","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1126\/science.284.5411.143","volume":"284","author":"MF Pittenger","year":"1999","unstructured":"Pittenger MF, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143\u20137.","journal-title":"Science"},{"key":"4788_CR48","unstructured":"Zuk PA, et al. Human adipose tissue is a source of multipotent stem cells D."},{"key":"4788_CR49","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1634\/stemcells.2004-0013","volume":"22","author":"H Wang","year":"2004","unstructured":"Wang H, et al. Mesenchymal stem cells in the Wharton\u2019s jelly of the human umbilical cord. Stem Cells. 2004;22:1330\u20137.","journal-title":"Stem Cells"},{"key":"4788_CR50","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/cmi.2014.70","volume":"12","author":"L-H Gu","year":"2015","unstructured":"Gu L-H, et al. Immunogenicity of allogeneic mesenchymal stem cells transplanted via different routes in diabetic rats. Cell Mol Immunol. 2015;12:444\u201355.","journal-title":"Cell Mol Immunol"},{"key":"4788_CR51","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/S0140-6736(04)16104-7","volume":"363","author":"K Le Blanc","year":"2004","unstructured":"Le Blanc K, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439\u201341.","journal-title":"Lancet"},{"key":"4788_CR52","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1002\/art.27548","volume":"62","author":"L Sun","year":"2010","unstructured":"Sun L, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 2010;62:2467\u201375.","journal-title":"Arthritis Rheum"},{"key":"4788_CR53","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nri2395","volume":"8","author":"A Uccelli","year":"2008","unstructured":"Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726\u201336.","journal-title":"Nat Rev Immunol"},{"key":"4788_CR54","unstructured":"\u300a\u6162\u52a0\u6025\u6027\u809d\u8870\u7aed\u8bca\u6cbb\u6307\u5357(2025\u5e74\u7248)\u300b\u89e3\u8bfb_\u5f90\u66fc&#26364."},{"key":"4788_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02318-4","volume":"10","author":"L Shi","year":"2025","unstructured":"Shi L, et al. Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia\/Ib results and immune modulation insights. Sig Transduct Target Ther. 2025;10:238.","journal-title":"Sig Transduct Target Ther"},{"key":"4788_CR56","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000002219","author":"R-J Wang","year":"2025","unstructured":"Wang R-J, et al. Prevention of liver fibrosis and hepatocellular carcinoma using antiplatelet drugs: A systematic review and Meta-analysis. J Clin Gastroenterol. 2025. https:\/\/doi.org\/10.1097\/MCG.0000000000002219.","journal-title":"J Clin Gastroenterol"},{"key":"4788_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-8-486","volume":"8","author":"R Ma","year":"2011","unstructured":"Ma R, et al. Hepatitis B virus infection and replication in human bone marrow mesenchymal stem cells. Virol J. 2011;8:486.","journal-title":"Virol J"},{"key":"4788_CR58","doi-asserted-by":"publisher","first-page":"6096","DOI":"10.3390\/ijms15046096","volume":"15","author":"Y Wang","year":"2014","unstructured":"Wang Y, et al. Human adipose-derived mesenchymal stem cells are resistant to HBV infection during differentiation into hepatocytes in vitro. IJMS. 2014;15:6096\u2013110.","journal-title":"IJMS"},{"key":"4788_CR59","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bbmt.2007.12.115","volume":"106","author":"K Alimoghaddam","year":"2008","unstructured":"Alimoghaddam K, et al. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Biology Blood Marrow Transplantation 14. 2008;106:41.","journal-title":"Biology Blood Marrow Transplantation 14"},{"key":"4788_CR60","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1007\/s12015-011-9322-y","volume":"8","author":"M El-Ansary","year":"2012","unstructured":"El-Ansary M, et al. Phase II trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis. Stem Cell Rev Rep. 2012;8:972\u201381.","journal-title":"Stem Cell Rev Rep"},{"key":"4788_CR61","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1089\/scd.2013.0500","volume":"23","author":"L Wang","year":"2014","unstructured":"Wang L, et al. Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis. Stem Cells Dev. 2014;23:2482\u20139.","journal-title":"Stem Cells Dev"},{"key":"4788_CR62","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1111\/jgh.12653","volume":"29","author":"L Xu","year":"2014","unstructured":"Xu L, et al. Randomized trial of autologous bone marrow mesenchymal stem cells transplantation for hepatitis B virus cirrhosis: regulation of Treg\/Th17 cells. J Gastroenterol Hepatol. 2014;29:1620\u20138.","journal-title":"J Gastroenterol Hepatol"},{"key":"4788_CR63","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/liv.12218","volume":"34","author":"YO Jang","year":"2014","unstructured":"Jang YO, et al. Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study. Liver Int. 2014;34:33\u201341.","journal-title":"Liver Int"},{"key":"4788_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/scrt459","author":"H Salama","year":"2014","unstructured":"Salama H, et al. Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease. Stem Cell Res Ther. 2014. https:\/\/doi.org\/10.1186\/scrt459.","journal-title":"Stem Cell Res Ther"},{"key":"4788_CR65","unstructured":"[Effect of umbilical. Cord mesenchymal stem cell transplantation on immune function and prognosis of patients with decompensated hepatitis B cirrhosis]."},{"key":"4788_CR66","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/hep.28693","volume":"64","author":"KT Suk","year":"2016","unstructured":"Suk KT, et al. Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: phase 2 trial. Hepatology. 2016;64:2185\u201397.","journal-title":"Hepatology"},{"key":"4788_CR67","unstructured":"[Safety and efficacy. of human umbilical cord derived-mesenchymal stem cell transplantation for treating patients with HBV-related decompensated cirrhosis]."},{"key":"4788_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-017-0541-2","volume":"8","author":"N Lanthier","year":"2017","unstructured":"Lanthier N, et al. Autologous bone marrow-derived cell transplantation in decompensated alcoholic liver disease: what is the impact on liver histology and gene expression patterns? Stem Cell Res Ther. 2017;8:88.","journal-title":"Stem Cell Res Ther"},{"key":"4788_CR69","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/1756-185X.13015","volume":"20","author":"J Liang","year":"2017","unstructured":"Liang J, et al. Effects of allogeneic mesenchymal stem cell transplantation in the treatment of liver cirrhosis caused by autoimmune diseases. Int J Rheum Dis. 2017;20:1219\u201326.","journal-title":"Int J Rheum Dis"},{"key":"4788_CR70","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/hep.29189","volume":"66","author":"B Lin","year":"2017","unstructured":"Lin B, et al. Allogeneic bone marrow\u2013derived mesenchymal stromal cells for hepatitis B virus\u2013related acute-on\u2010chronic liver failure: a randomized controlled trial. Hepatology. 2017;66:209\u201319.","journal-title":"Hepatology"},{"key":"4788_CR71","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.1177\/0963689719884885","volume":"28","author":"K-C Huang","year":"2019","unstructured":"Huang K-C, et al. Transplantation with GXHPC1 for liver cirrhosis: phase 1 trial. Cell Transpl. 2019;28:S100\u201311.","journal-title":"Cell Transpl"},{"key":"4788_CR72","doi-asserted-by":"crossref","unstructured":"Schacher FC, Silva MPD, Silla A, \u00c1lvares-da-Silva MR. Bone marrow mesenchymal stem cells in acute-on-chronic liver failure grades 2 and 3: a phase I-II randomized clinical trial. Can J Gastroenterol Hepatol.\u00a02021;1\u20139.","DOI":"10.1155\/2021\/3662776"},{"key":"4788_CR73","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s12072-021-10199-2","volume":"15","author":"M Shi","year":"2021","unstructured":"Shi M, et al. Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial. Hepatol Int. 2021;15:1431\u201341.","journal-title":"Hepatol Int"},{"key":"4788_CR74","unstructured":"Zhao D-C, et al. Bone marrow-derived mesenchymal stem cells protect against experimental liver fibrosis in rats."},{"key":"4788_CR75","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.clinbiochem.2007.04.017","volume":"40","author":"MT Abdel Aziz","year":"2007","unstructured":"Abdel Aziz MT, et al. Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis. Clin Biochem. 2007;40:893\u20139.","journal-title":"Clin Biochem"},{"key":"4788_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-78","author":"GA Nasir","year":"2013","unstructured":"Nasir GA, et al. Mesenchymal stem cells and interleukin-6 attenuate liver fibrosis in mice. J Transl Med. 2013. https:\/\/doi.org\/10.1186\/1479-5876-11-78.","journal-title":"J Transl Med"},{"key":"4788_CR77","doi-asserted-by":"crossref","unstructured":"Rengasamy M, et al. Transplantation of human bone marrow mesenchymal stromal cells reduces liver fibrosis more effectively than wharton\u2019s jelly mesenchymal stromal cells. Stem Cell Res Ther 2017;8.","DOI":"10.1186\/s13287-017-0595-1"},{"key":"4788_CR78","doi-asserted-by":"publisher","first-page":"8152","DOI":"10.3748\/wjg.v23.i46.8152","volume":"23","author":"G-Z Zhang","year":"2017","unstructured":"Zhang G-Z, Sun H-C, Zheng L-B, Guo J-B, Zhang X-L. Vivo hepatic differentiation potential of human umbilical cord-derived mesenchymal stem cells: therapeutic effect on liver fibrosis\/cirrhosis. WJG. 2017;23:8152\u201368.","journal-title":"WJG"},{"key":"4788_CR79","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/sctm.18-0105","volume":"8","author":"Y Watanabe","year":"2019","unstructured":"Watanabe Y, et al. Mesenchymal stem cells and induced bone marrow-derived macrophages synergistically improve liver fibrosis in mice. Stem Cells Transl Med. 2019;8:271\u201384.","journal-title":"Stem Cells Transl Med"},{"key":"4788_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-020-01763-y","author":"N Liao","year":"2020","unstructured":"Liao N, et al. Antioxidant preconditioning improves therapeutic outcomes of adipose tissue-derived mesenchymal stem cells through enhancing intrahepatic engraftment efficiency in a mouse liver fibrosis model. Stem Cell Res Ther. 2020. https:\/\/doi.org\/10.1186\/s13287-020-01763-y.","journal-title":"Stem Cell Res Ther"},{"key":"4788_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-022-02729-y","author":"R Xu","year":"2022","unstructured":"Xu R, et al. Ccr2-overexpressing mesenchymal stem cells targeting damaged liver enhance recovery of acute liver failure. Stem Cell Res Ther. 2022. https:\/\/doi.org\/10.1186\/s13287-022-02729-y.","journal-title":"Stem Cell Res Ther"},{"key":"4788_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-023-03446-w","author":"Y Takayama","year":"2023","unstructured":"Takayama Y, et al. Efficient delivery of mesenchymal stem\/stromal cells to injured liver by surface pegylation. Stem Cell Res Ther. 2023. https:\/\/doi.org\/10.1186\/s13287-023-03446-w.","journal-title":"Stem Cell Res Ther"},{"key":"4788_CR83","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/stcltm\/szae028","volume":"13","author":"T Huang","year":"2024","unstructured":"Huang T, et al. Bone mesenchymal stem cells improve cholestatic liver fibrosis by targeting ULK1 to regulate autophagy through PI3K\/AKT\/mTOR pathway. Stem Cells Transl Med. 2024;13:648\u201360.","journal-title":"Stem Cells Transl Med"},{"key":"4788_CR84","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i10.1048","volume":"18","author":"W Zhao","year":"2012","unstructured":"Zhao W. Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis. WJG. 2012;18:1048.","journal-title":"WJG"},{"key":"4788_CR85","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1172\/JCI200522675","volume":"115","author":"JS Duffield","year":"2005","unstructured":"Duffield JS, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest. 2005;115:56\u201365.","journal-title":"J Clin Invest"},{"key":"4788_CR86","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.stem.2017.07.011","volume":"21","author":"E El Agha","year":"2017","unstructured":"El Agha E, et al. Mesenchymal stem cells in fibrotic disease. Cell Stem Cell. 2017;21:166\u201377.","journal-title":"Cell Stem Cell"},{"key":"4788_CR87","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41423-023-00983-5","volume":"20","author":"X Yang","year":"2023","unstructured":"Yang X, et al. Mesenchymal stromal cells in hepatic fibrosis\/cirrhosis: from pathogenesis to treatment. Cell Mol Immunol. 2023;20:583\u201399.","journal-title":"Cell Mol Immunol"},{"key":"4788_CR88","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/hep.24621","volume":"55","author":"J Jiao","year":"2012","unstructured":"Jiao J, et al. Dendritic cell regulation of carbon tetrachloride\u2013induced murine liver fibrosis regression. Hepatology. 2012;55:244\u201355.","journal-title":"Hepatology"},{"key":"4788_CR89","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/01.tp.0000244572.24780.54","volume":"83","author":"R Ramasamy","year":"2007","unstructured":"Ramasamy R, et al. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation. 2007;83:71\u20136.","journal-title":"Transplantation"},{"key":"4788_CR90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039307","volume":"7","author":"J Li","year":"2012","unstructured":"Li J, et al. Significance of the balance between regulatory T (Treg) and T helper 17 (Th17) cells during hepatitis B virus related liver fibrosis. PLoS One. 2012;7:e39307.","journal-title":"PLoS One"},{"key":"4788_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-019-1447-y","volume":"10","author":"F Liu","year":"2019","unstructured":"Liu F, et al. MSC-secreted TGF-\u03b2 regulates lipopolysaccharide-stimulated macrophage M2-like polarization via the Akt\/FoxO1 pathway. Stem Cell Res Ther. 2019;10:345.","journal-title":"Stem Cell Res Ther"},{"key":"4788_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-020-01894-2","volume":"11","author":"F Liu","year":"2020","unstructured":"Liu F, et al. Overexpressing TGF-\u03b21 in mesenchymal stem cells attenuates organ dysfunction during CLP-induced septic mice by reducing macrophage-driven inflammation. Stem Cell Res Ther. 2020;11:378.","journal-title":"Stem Cell Res Ther"},{"key":"4788_CR93","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1007\/s12015-013-9455-2","volume":"9","author":"MH Abumaree","year":"2013","unstructured":"Abumaree MH, et al. Human placental mesenchymal stem cells (pMSCs) play a role as immune suppressive cells by shifting macrophage differentiation from inflammatory M1 to anti-inflammatory M2 macrophages. Stem Cell Rev Rep. 2013;9:620\u201341.","journal-title":"Stem Cell Rev Rep"},{"key":"4788_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/srep37566","volume":"6","author":"Y Deng","year":"2016","unstructured":"Deng Y, et al. Umbilical cord-derived mesenchymal stem cells instruct monocytes towards an IL10-producing phenotype by secreting IL6 and HGF. Sci Rep. 2016;6:37566.","journal-title":"Sci Rep"},{"key":"4788_CR95","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-025-04535-8","volume":"16","author":"V Bozorgi","year":"2025","unstructured":"Bozorgi V, Babaahmadi M, Salehi M, Vafaeimanesh J, Hajizadeh-Saffar E. From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy. Stem Cell Res Ther. 2025;16:421.","journal-title":"Stem Cell Res Ther"},{"key":"4788_CR96","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1042\/CBI20110634","volume":"36","author":"K Cho","year":"2012","unstructured":"Cho K, Woo S, Seoh J, Han H, Ryu K. Mesenchymal stem cells restore CCl4 -induced liver injury by an antioxidative process. Cell Biol Int. 2012;36:1267\u201374.","journal-title":"Cell Biol Int"},{"key":"4788_CR97","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/stem.2575","volume":"35","author":"DG Phinney","year":"2017","unstructured":"Phinney DG, Pittenger MF. Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells. 2017;35:851\u20138.","journal-title":"Stem Cells"},{"key":"4788_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8090350","volume":"8","author":"M-J Hsu","year":"2020","unstructured":"Hsu M-J, et al. Mitochondrial transfer by human mesenchymal stromal cells ameliorates hepatocyte lipid load in a mouse model of NASH. Biomedicines. 2020;8:350.","journal-title":"Biomedicines"},{"key":"4788_CR99","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1096\/fj.201800131RR","volume":"33","author":"J Yao","year":"2019","unstructured":"Yao J, et al. Extracellular vesicles derived from human umbilical cord mesenchymal stem cells alleviate rat hepatic ischemia-reperfusion injury by suppressing oxidative stress and neutrophil inflammatory response. FASEB J. 2019;33:1695\u2013710.","journal-title":"FASEB J"},{"key":"4788_CR100","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1248\/bpb.b16-00891","volume":"40","author":"N Kumeda","year":"2017","unstructured":"Kumeda N, et al. Characterization of membrane integrity and morphological stability of human salivary exosomes. Biol Pharm Bull. 2017;40:1183\u201391.","journal-title":"Biol Pharm Bull"},{"key":"4788_CR101","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1053\/j.gastro.2018.06.083","volume":"155","author":"A Mansouri","year":"2018","unstructured":"Mansouri A, Gattolliat C-H, Asselah T. Mitochondrial dysfunction and signaling in chronic liver diseases. Gastroenterology. 2018;155:629\u201347.","journal-title":"Gastroenterology"},{"key":"4788_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03374-0","volume":"12","author":"J Wang","year":"2021","unstructured":"Wang J, Ding H, Pan C, Shi X, Ren H. Mesenchymal stem cells ameliorate lipid metabolism through reducing mitochondrial damage of hepatocytes in the treatment of post-hepatectomy liver failure. Cell Death Dis. 2021;12:111.","journal-title":"Cell Death Dis"},{"key":"4788_CR103","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/jcmm.12036","volume":"17","author":"JL Carvalho","year":"2013","unstructured":"Carvalho JL, et al. Priming mesenchymal stem cells boosts stem cell therapy to treat myocardial infarction. J Cell Mol Med. 2013;17:617\u201325.","journal-title":"J Cell Mol Med"},{"key":"4788_CR104","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13287-019-1224-y","volume":"10","author":"NDC Noronha","year":"2019","unstructured":"Noronha NDC, et al. Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res Ther. 2019;10:131.","journal-title":"Stem Cell Res Ther"},{"key":"4788_CR105","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ebiom.2018.01.002","volume":"28","author":"DS Kim","year":"2018","unstructured":"Kim DS, et al. Enhanced immunosuppressive properties of human mesenchymal stem cells primed by Interferon-\u03b3. EBioMedicine. 2018;28:261\u201373.","journal-title":"EBioMedicine"},{"key":"4788_CR106","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.61.2.6","volume":"61","author":"B Mead","year":"2020","unstructured":"Mead B, Chamling X, Zack DJ, Ahmed Z, Tomarev S. TNF\u03b1-mediated priming of mesenchymal stem cells enhances their neuroprotective effect on retinal ganglion cells. Invest Ophthalmol Vis Sci. 2020;61:6.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4788_CR107","doi-asserted-by":"publisher","first-page":"615","DOI":"10.12659\/AOT.909381","volume":"23","author":"T Ma","year":"2018","unstructured":"Ma T, et al. Interleukin 17 (IL-17)-induced mesenchymal stem cells prolong the survival of allogeneic skin grafts. Ann Transplant. 2018;23:615\u201321.","journal-title":"Ann Transplant"},{"key":"4788_CR108","doi-asserted-by":"publisher","first-page":"626","DOI":"10.7150\/ijms.8228","volume":"11","author":"J Liu","year":"2014","unstructured":"Liu J, Pan G, Liang T, Huang P. HGF\/c-Met signaling mediated mesenchymal stem cell-induced liver recovery in intestinal ischemia reperfusion model. Int J Med Sci. 2014;11:626\u201333.","journal-title":"Int J Med Sci"},{"key":"4788_CR109","doi-asserted-by":"crossref","unstructured":"Nie H, et al. IL-1 \u03b2 Pretreatment improves the efficacy of mesenchymal stem cells on acute liver failure by enhancing CXCR4 expression. Stem Cells Int. 2020;1\u201311.","DOI":"10.1155\/2020\/1498315"},{"key":"4788_CR110","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/jcmm.17698","volume":"27","author":"A Garg","year":"2023","unstructured":"Garg A, et al. TGF\u03b21 priming enhances CXCR3 -mediated mesenchymal stromal cell engraftment to the liver and enhances anti\u2010inflammatory efficacy. J Cell Mol Med. 2023;27:864\u201378.","journal-title":"J Cell Mol Med"},{"key":"4788_CR111","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-017-0543-0","volume":"8","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, et al. Autophagy mediates the beneficial effect of hypoxic preconditioning on bone marrow mesenchymal stem cells for the therapy of myocardial infarction. Stem Cell Res Ther. 2017;8:89.","journal-title":"Stem Cell Res Ther"},{"key":"4788_CR112","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/jcmm.14788","volume":"24","author":"C Hu","year":"2020","unstructured":"Hu C, Wu Z, Li L. Pre-treatments enhance the therapeutic effects of mesenchymal stem cells in liver diseases. J Cell Mol Med. 2020;24:40\u20139.","journal-title":"J Cell Mol Med"},{"key":"4788_CR113","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.reth.2019.08.005","volume":"11","author":"Y Kojima","year":"2019","unstructured":"Kojima Y, et al. Mesenchymal stem cells cultured under hypoxic conditions had a greater therapeutic effect on mice with liver cirrhosis compared to those cultured under normal oxygen conditions. Regen Ther. 2019;11:269\u201381.","journal-title":"Regen Ther"},{"key":"4788_CR114","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-021-02480-w","volume":"12","author":"J Liu","year":"2021","unstructured":"Liu J, et al. Hypoxic preconditioning rejuvenates mesenchymal stem cells and enhances neuroprotection following intracerebral hemorrhage via the miR-326-mediated autophagy. Stem Cell Res Ther. 2021;12:413.","journal-title":"Stem Cell Res Ther"},{"key":"4788_CR115","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1038\/s41375-018-0151-8","volume":"32","author":"Y Kim","year":"2018","unstructured":"Kim Y, et al. Small hypoxia-primed mesenchymal stem cells attenuate graft-versus-host disease. Leukemia. 2018;32:2672\u201384.","journal-title":"Leukemia"},{"key":"4788_CR116","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.bbrc.2010.09.076","volume":"401","author":"H Liu","year":"2010","unstructured":"Liu H, et al. Hypoxic preconditioning advances CXCR4 and CXCR7 expression by activating HIF-1\u03b1 in MSCs. Biochem Biophys Res Commun. 2010;401:509\u201315.","journal-title":"Biochem Biophys Res Commun"},{"key":"4788_CR117","doi-asserted-by":"publisher","DOI":"10.1186\/scrt234","volume":"4","author":"J Yu","year":"2013","unstructured":"Yu J, et al. Hypoxia preconditioned bone marrow mesenchymal stem cells promote liver regeneration in a rat massive hepatectomy model. Stem Cell Res Ther. 2013;4:83.","journal-title":"Stem Cell Res Ther"},{"key":"4788_CR118","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-019-1404-9","volume":"10","author":"N Liao","year":"2019","unstructured":"Liao N, et al. Antioxidants inhibit cell senescence and preserve stemness of adipose tissue-derived stem cells by reducing ROS generation during long-term in vitro expansion. Stem Cell Res Ther. 2019;10:306.","journal-title":"Stem Cell Res Ther"},{"key":"4788_CR119","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-020-01763-y","volume":"11","author":"N Liao","year":"2020","unstructured":"Liao N, et al. Antioxidant preconditioning improves therapeutic outcomes of adipose tissue-derived mesenchymal stem cells through enhancing intrahepatic engraftment efficiency in a mouse liver fibrosis model. Stem Cell Res Ther. 2020;11:237.","journal-title":"Stem Cell Res Ther"},{"key":"4788_CR120","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00441-017-2604-1","volume":"369","author":"K Mortezaee","year":"2017","unstructured":"Mortezaee K, et al. Retracted article: preconditioning with melatonin improves therapeutic outcomes of bone marrow-derived mesenchymal stem cells in targeting liver fibrosis induced by CCl4. Cell Tissue Res. 2017;369:303\u201312.","journal-title":"Cell Tissue Res"},{"key":"4788_CR121","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.reth.2021.07.002","volume":"18","author":"T Iwasawa","year":"2021","unstructured":"Iwasawa T, et al. Combination therapy of Juzentaihoto and mesenchymal stem cells attenuates liver damage and regresses fibrosis in mice. Regen Ther. 2021;18:231\u201341.","journal-title":"Regen Ther"},{"key":"4788_CR122","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.1182\/blood-2010-10-311464","volume":"118","author":"D Sarkar","year":"2011","unstructured":"Sarkar D, et al. Engineered cell homing. Blood. 2011;118:e184\u201391.","journal-title":"Blood"},{"key":"4788_CR123","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/stem.1656","volume":"32","author":"H Li","year":"2014","unstructured":"Li H, et al. CCR7 guides migration of mesenchymal stem cell to secondary lymphoid organs: A novel approach to separate GvHD from GvL effect. Stem Cells. 2014;32:1890\u2013903.","journal-title":"Stem Cells"},{"key":"4788_CR124","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-015-0007-0","volume":"4","author":"JD Robles","year":"2015","unstructured":"Robles JD, et al. Immunosuppressive mechanisms of human bone marrow derived mesenchymal stromal cells in BALB\/c host graft versus host disease murine models. Exp Hematol Oncol. 2015;4:13.","journal-title":"Exp Hematol Oncol"},{"key":"4788_CR125","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.ymthe.2017.04.004","volume":"25","author":"X Zhang","year":"2017","unstructured":"Zhang X, et al. CXCR5-overexpressing mesenchymal stromal cells exhibit enhanced homing and can decrease contact hypersensitivity. Mol Ther. 2017;25:1434\u201347.","journal-title":"Mol Ther"},{"key":"4788_CR126","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0723-8","volume":"12","author":"Y Yang","year":"2019","unstructured":"Yang Y, et al. Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells. J Hematol Oncol. 2019;12:46.","journal-title":"J Hematol Oncol"},{"key":"4788_CR127","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ijcard.2015.08.117","volume":"201","author":"SC Suresh","year":"2015","unstructured":"Suresh SC, et al. Thioredoxin-1 (Trx1) engineered mesenchymal stem cell therapy increased pro-angiogenic factors, reduced fibrosis and improved heart function in the infarcted rat myocardium. Int J Cardiol. 2015;201:517\u201328.","journal-title":"Int J Cardiol"},{"key":"4788_CR128","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.canlet.2009.08.031","volume":"290","author":"P Gao","year":"2010","unstructured":"Gao P, Ding Q, Wu Z, Jiang H, Fang Z. Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Lett. 2010;290:157\u201366.","journal-title":"Cancer Lett"},{"key":"4788_CR129","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.3892\/etm.2014.1918","volume":"8","author":"J Han","year":"2014","unstructured":"Han J, Zhao J, Xu J, Wen Y. Mesenchymal stem cells genetically modified by lentivirus-mediated interleukin-12 inhibit malignant ascites in mice. Exp Ther Med. 2014;8:1330\u20134.","journal-title":"Exp Ther Med"},{"key":"4788_CR130","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/stem.2801","volume":"36","author":"T Relation","year":"2018","unstructured":"Relation T, et al. Intratumoral delivery of interferon\u03b3-secreting mesenchymal stromal cells repolarizes tumor-associated macrophages and suppresses neuroblastoma proliferation in vivo. Stem Cells. 2018;36:915\u201324.","journal-title":"Stem Cells"},{"key":"4788_CR131","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/gt.2010.170","volume":"18","author":"SH Seo","year":"2011","unstructured":"Seo SH, et al. The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther. 2011;18:488\u201395.","journal-title":"Gene Ther"},{"key":"4788_CR132","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2410579121","volume":"121","author":"F Zhu","year":"2024","unstructured":"Zhu F, et al. In situ licensing of mesenchymal stem cell immunomodulatory function via BMP-2 induced developmental process. Proc Natl Acad Sci USA. 2024;121:e2410579121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4788_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2025.102317","author":"A Kumar","year":"2025","unstructured":"Kumar A, et al. Efficacy and safety of everolimus with reduced tacrolimus versus standard tacrolimus in liver transplant recipients: a systematic review and meta-analysis of randomized controlled trials. Transpl Immunol. 2025. https:\/\/doi.org\/10.1016\/j.trim.2025.102317.","journal-title":"Transpl Immunol."},{"key":"4788_CR134","doi-asserted-by":"publisher","DOI":"10.1097\/LVT.0000000000000750","author":"J Rhu","year":"2025","unstructured":"Rhu J, et al. Long-term outcome of the initial cases with recipient-side minimal invasive liver transplantation: Single-center comparison study. Liver Transpl. 2025. https:\/\/doi.org\/10.1097\/LVT.0000000000000750.","journal-title":"Liver Transpl"},{"key":"4788_CR135","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-024-04127-y","volume":"16","author":"W-C Huang","year":"2025","unstructured":"Huang W-C, Li Y-C, Chen P-X, Ma KS-K, Wang L-T. Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials. Stem Cell Res Ther. 2025;16:3.","journal-title":"Stem Cell Res Ther"},{"key":"4788_CR136","doi-asserted-by":"crossref","unstructured":"Eggenhofer E, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immun. 2012.","DOI":"10.3389\/fimmu.2012.00297"},{"key":"4788_CR137","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41423-023-01018-9","volume":"20","author":"C Giacomini","year":"2023","unstructured":"Giacomini C, Gran\u00e9li C, Hicks R, Dazzi F. The critical role of apoptosis in mesenchymal stromal cell therapeutics and implications in homeostasis and normal tissue repair. Cell Mol Immunol. 2023;20:570\u201382.","journal-title":"Cell Mol Immunol"},{"key":"4788_CR138","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/stem.2779","volume":"36","author":"SFH De Witte","year":"2018","unstructured":"De Witte SFH, et al. Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells. Stem Cells. 2018;36:602\u201315.","journal-title":"Stem Cells"},{"key":"4788_CR139","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-021-00584-z","author":"Y Li","year":"2021","unstructured":"Li Y. Mesenchymal stem cells attenuate liver fibrosis by targeting Ly6Chi\/lo macrophages through activating the cytokine-paracrine and apoptotic pathways. Cell Death Discov. 2021. https:\/\/doi.org\/10.1038\/s41420-021-00584-z.","journal-title":"Cell Death Discov"},{"key":"4788_CR140","doi-asserted-by":"publisher","first-page":"5753","DOI":"10.2147\/IJN.S192779","volume":"14","author":"R Geetha Bai","year":"2019","unstructured":"Geetha Bai R, Muthoosamy K, Manickam S, Hilal-Alnaqbi A. Graphene-based 3D scaffolds in tissue engineering: fabrication, applications, and future scope in liver tissue engineering. IJN Volume. 2019;14:5753\u201383.","journal-title":"IJN Volume"},{"issue":"1","key":"4788_CR141","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201804041","volume":"31","author":"N Ashammakhi","year":"2019","unstructured":"Ashammakhi N, et al. Minimally invasive and regenerative therapeutics. Adv Mater. 2019;31(1):1804041.","journal-title":"Adv Mater"},{"key":"4788_CR142","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1089\/hum.2007.034","volume":"18","author":"T Hakkarainen","year":"2007","unstructured":"Hakkarainen T, et al. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther. 2007;18:627\u201341.","journal-title":"Hum Gene Ther"},{"key":"4788_CR143","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1634\/stemcells.2007-0758","volume":"26","author":"AM Sonabend","year":"2008","unstructured":"Sonabend AM, et al. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells. 2008;26:831\u201341.","journal-title":"Stem Cells"},{"key":"4788_CR144","doi-asserted-by":"crossref","unstructured":"Du W, et al. Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. Proc Natl Acad Sci USA.\u00a02017;114.","DOI":"10.1073\/pnas.1700363114"},{"key":"4788_CR145","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1292","author":"EK Mader","year":"2009","unstructured":"Mader EK, et al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Cancer Ther. 2009. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1292.","journal-title":"Cancer Ther"},{"key":"4788_CR146","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jhep.2013.07.010","volume":"59","author":"H-T Ong","year":"2013","unstructured":"Ong H-T, et al. Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. J Hepatol. 2013;59:999\u20131006.","journal-title":"J Hepatol"},{"key":"4788_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07443-0","volume":"16","author":"Y Shi","year":"2025","unstructured":"Shi Y, et al. Engineered mesenchymal stem\/stromal cells against cancer. Cell Death Dis. 2025;16:113.","journal-title":"Cell Death Dis"},{"key":"4788_CR148","unstructured":"Harnessing engineered extracellular vesicles from mesenchymal stem cells as therapeutic scaffolds for bone-related. Diseases-Yu-2024-Advanced Functional Materials-Wiley Online Library. https:\/\/advanced.onlinelibrary.wiley.com\/doi\/abs\/10.1002\/adfm.202402861"},{"key":"4788_CR149","unstructured":"\u95f4\u5145\u8d28\u5e72\u7ec6\u80de\u53ca\u7ec6\u80de\u5916\u56ca\u6ce1\u6cbb\u7597\u80ba\u7ea4\u7ef4\u5316\u7684\u73b0\u72b6\u4e0e\u672a\u6765_\u738b\u8273&#38451."},{"key":"4788_CR150","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/s41591-020-1042-x","volume":"26","author":"EJ Topol","year":"2020","unstructured":"Topol EJ. Welcoming new guidelines for AI clinical research. Nat Med. 2020;26:1318\u201320.","journal-title":"Nat Med"},{"key":"4788_CR151","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.drudis.2018.11.014","volume":"24","author":"K-K Mak","year":"2019","unstructured":"Mak K-K, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019;24:773\u201380.","journal-title":"Drug Discov Today"},{"key":"4788_CR152","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18071-x","volume":"11","author":"I Piazza","year":"2020","unstructured":"Piazza I, et al. A machine learning-based chemoproteomic approach to identify drug targets and binding sites in complex proteomes. Nat Commun. 2020;11:4200.","journal-title":"Nat Commun"}],"container-title":["Stem Cell Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04788-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-025-04788-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04788-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T14:13:50Z","timestamp":1764339230000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-025-04788-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":152,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4788"],"URL":"https:\/\/doi.org\/10.1186\/s13287-025-04788-3","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors of this paper agree to participate in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"666"}}